



# Ceftriaxone & Tazobactam for Injection

**SUPRAVA™ TZ**

सुप्रा टि ज़ेड

## COMPOSITION

Each Vial contains  
Sterile Ceftriaxone Sodium IP  
Equivalent to Ceftriaxone 1g  
Sterile Tazobactam Sodium  
Equivalent to Tazobactam 125mg  
Powder for reconstitution (intravenous (IV)/intramuscular (IM).

## PHARMACOLOGY

### Pharmacodynamics

Ceftriaxone is a 2-aminothiazolyl methoxymino third-generation cephalosporin derivative. Ceftriaxone, a bactericidal antimicrobial, inhibits bacterial cell wall synthesis of actively dividing cells by binding to one or more penicillin-binding proteins (PBPs). These proteins are associated with the bacterial cell membrane and probably serve in synthesis. The result is the formation of a defective cell wall that is osmotically unstable. Bacterial species have a unique set of PBPs. The affinity pattern of ceftriaxone for the PBPs for different bacterial species affects the drug's antimicrobial spectrum of activity. It is also felt that cephalosporins, as well as penicillins, may increase the breakdown of the cell wall of the bacteria by decreasing the availability of an inhibitor of murein hydrolase, an enzyme involved in cell division. If unimposed, this enzyme can destroy the integrity of the cell wall.

Tazobactam is a penicillinate sulfone, structurally related to sulbactam. Being a beta-lactamase inhibitor, it is synergistic with many beta-lactamase labile drugs such as penicillins and cephalosporins. Tazobactam inhibits all beta-lactamases inhibited by clavulanic acid, but, in addition, it also has some activity against chromosomally-mediated induced (or derepressed) enzymes of *Morganella morganii*, *Citrobacter freundii*, *Enterobacter cloacae*, *Serratia marcescens* and *Pseudomonas aeruginosa*. Tazobactam also appears to be a weaker enzyme inducer than other beta-lactamase inhibitors.

### Combination of Tazobactam and Ceftriaxone

The combination of tazobactam and ceftriaxone is active against all the organisms sensitive to ceftriaxone. In addition, it demonstrates synergistic activity (reduction in minimal inhibitory concentrations [MICs] for the combination versus those of each component) in a variety of organisms.

## Pharmacokinetics

### Distribution

Ceftriaxone: 98% bound to plasma proteins; crosses the blood brain barrier. Tazobactam: About 30% bound to plasma proteins; widely distributed to tissues and body fluids.

### Excretion

Ceftriaxone: Elimination half-life is about 8.7 hours; 33-67% removed as unchanged drug. Tazobactam: Removed mainly via kidneys with 80% of an administered dose as unchanged drug.

## INDICATIONS

It is mainly indicated in the following conditions:

- Lower respiratory tract infections and community-acquired pneumonia
- Acute bacterial otitis media
- Skin and skin structure infections
- Urinary tract infections
- Uncomplicated gonorrhoea
- Pelvic inflammatory disease
- Bacterial septicemia
- Bone and joint infections
- Intra-abdominal infections
- Bacterial meningitis
- Peri-operative prophylaxis of infections associated with surgery

## CONTRAINDICATIONS

Hyper-sensitivity to cephalosporins and beta-lactamase inhibitors.

Neonates (<= 28 days)

Hyperbilirubinemic neonates, especially prematures, should not be treated with ceftriaxone. In vitro studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin and bilirubin encephalopathy can possibly develop in these patients. In neonates, ceftriaxone must not be co-administered with calcium-containing I.V. solutions, including continuous calcium-containing infusions such as parenteral nutrition, because of the risk of precipitation of the ceftriaxone-calcium salt.

## WARNINGS AND PRECAUTIONS

This product should be given cautiously to penicillin-sensitive patients. Serious acute hypersensitivity reactions may require the use of subcutaneous epinephrine and other emergency measures.

*Clostridium difficile* associated diarrhea has been reported with nearly all antibacterial agents, including ceftriaxone/tazobactam, and may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of antibacterial agents.

An immune mediated hemolytic anemia has been observed in patients receiving cephalosporin class antibacterials including Ceftriaxone. If a patient develops anemia while on ceftriaxone, the diagnosis of a cephalosporin associated anemia should be considered and ceftriaxone stopped until the etiology is determined. Although transient elevations of BUN and serum creatinine have been observed, at the recommended dosages, the nephrotoxic potential of ceftriaxone/tazobactam is similar to that of other cephalosporins.

Alterations in prothrombin times have occurred infrequently in patients treated with ceftriaxone/tazobactam. Patients with impaired vitamin K synthesis or low vitamin K stores (eg, chronic hepatic disease and malnutrition) may require monitoring of prothrombin time during Ceftriaxone and Tazobactam treatment.

It should also be prescribed with caution in individuals with a history of gastrointestinal disease, especially colitis. There have been reports of sonographic abnormalities in the gall bladder of patients treated with ceftriaxone/tazobactam; some of these patients also had symptoms of gall bladder disease. The condition appears to be transient and reversible upon the discontinuation of ceftriaxone/tazobactam and the institution of conservative management. Cases of pancreatitis, possibly secondary to biliary obstruction, have been reported rarely in patients treated with ceftriaxone/tazobactam.

## Renal Impairment

Ceftriaxone is excreted via both biliary and renal excretion. Therefore, patients with renal failure normally require no dosage adjustment when the usual doses of ceftriaxone/tazobactam are administered, but concentrations of the drug in the serum should be monitored periodically. If evidence of accumulation exists, the dosage should be decreased accordingly.

No data are available in the case of pediatric patients with impaired renal function.

## Hepatic Impairment

Dosage adjustments should not be necessary in patients with hepatic dysfunction; however, in patients with both hepatic dysfunction and significant renal disease, the dosage of ceftriaxone/tazobactam should not exceed 2 gm daily without close monitoring of serum concentrations. No data are available in the case of pediatric patients with impaired hepatic function.

## Pregnancy

ceftriaxone/tazobactam Injection should be used during pregnancy only if clearly needed.

## Lactation

Low concentrations of ceftriaxone/tazobactam are excreted in human milk. Hence, caution should be exercised when ceftriaxone/tazobactam is administered to a nursing mother.

## Pediatric Use

Ceftriaxone/tazobactam should not be administered to hyperbilirubinemic neonates, especially prematures.

## Geriatric Use

The pharmacokinetics of ceftriaxone/tazobactam were only minimally altered in geriatric patients compared to healthy adult subjects and dosage adjustments are not necessary for geriatric patients with ceftriaxone/tazobactam dosages up to 2 grams per day.

## UNDESIRABLE EFFECTS

Local reactions-pain, induration and tenderness was 1% overall. Phlebitis was reported in <1% after IV administration. Hypersensitivity-rash (1.7%). Less frequently reported (<1%) were pruritus, fever or chills. Hematologic-eosinophilia (6%), thrombocytosis (5.1%) and



# Ceftriaxone & Tazobactam for Injection

**SUPRAVA™ TZ**

सुप्रवा टि ज़ेड

leukopenia (2.1%). Less frequently reported (<1%) were anemia, hemolytic anemia, neutropenia, lymphopenia, thrombocytopenia and prolongation of the prothrombin time.

Gastrointestinal-diarrhea (2.7%). Less frequently reported (<1%) were nausea or vomiting, and dysgeusia. Hepatic-elevations of SGOT (3.1%) or SGPT (3.3%). Less frequently reported (<1%) were elevations of alkaline phosphatase and bilirubin.

Renal-elevations of the BUN (1.2%). Less frequently reported (<1%) were elevations of creatinine and the presence of casts in the urine. Central nervous system-headache or dizziness were reported occasionally (<1%). Genitourinary-monomiliasis or vaginitis were reported occasionally (<1%).

Miscellaneous-diaphoresis and flushing were reported occasionally (<1%). Other rarely observed adverse reactions (<0.1%) include abdominal pain, agranulocytosis, allergic pneumonitis, anaphylaxis, basophilia, biliary lithiasis, bronchospasm, colitis, dyspepsia, epistaxis, flatulence, gallbladder sludge, glycosuria, hematuria, jaundice, leukocytosis, lymphocytosis, monocytosis, nephrolithiasis, palpitations, a decrease in the prothrombin time, renal precipitations, seizures, and serum sickness.

Gastrointestinal-stomatitis and glossitis. Genitourinary-oliguria. Dermatologic-exanthema, allergic dermatitis, urticaria, edema. As with many medications, isolated cases of severe cutaneous adverse reactions (erythema multiforme, Stevens-Johnson syndrome or Lyell's syndrome/toxic epidermal necrolysis) have been reported.

## OVERDOSAGE

In the case of overdosage, drug concentration would not be reduced by hemodialysis or peritoneal dialysis. There is no specific antidote. Treatment of overdosage should be symptomatic.

## DOSAGE AND ADMINISTRATION

Adults: The usual adult dose is 1000/125 mg of ceftriaxone/tazobactam given once a day (or in equally divided doses twice a day) depending upon the severity of the infection. The total daily dose should not exceed 4 gm (in terms of ceftriaxone).

For pre-operative use (surgical prophylaxis), a single I.V. dose of 1 gm administered half an hour to 2 hours before surgery is recommended. Generally, ceftriaxone/tazobactam should be continued for at least 2 days after the signs and symptoms of infection have disappeared. The usual duration of therapy is 4-14 days; in complicated infections, longer therapy may be required. When treating Streptococci pyogenes, the therapy should be continued for at least 10 days.

Ceftriaxone may be administered by deep intramuscular injection, or as a slow intravenous injection/ infusion, after reconstitution of the solution according to the directions given below.

Pediatric Patients: For the treatment of serious infections, the recommended dose is 50-75 mg/kg (in terms of ceftriaxone) given in divided doses every 12 hours. The total daily dose should not exceed 2 gm (in terms of ceftriaxone). For the treatment of acute bacterial otitis media, a single intramuscular dose of 50 mg/kg (not to exceed 1 gram) is recommended

## Directions for Use

I.V. injection should be administered over at least 2-4 minutes. I.V. infusion should be over a period of 30 minutes. After reconstitution the solution should be administered by deep I.M. injection. Doses greater than 1g should be divided and injected at more than one site.

Reconstitute ceftriaxone/tazobactam with the appropriate diluent, e.g., Water for Injection IP, Normal Saline Water, or Dextrose Solutions.

Strength	Amount of diluent for IM (ml)	Amount of diluent for IV (ml)
1g	3.6	9.6

Use reconstituted solution in the vial immediately.

## INCOMPATIBILITY

Vancomycin, aminoglycosides, and fluconazole are physically incompatible with ceftriaxone/tazobactam in admixtures. When any of these drugs are to be administered concomitantly by intermittent intravenous infusion, it is recommended that they be given sequentially, with thorough flushing of the intravenous lines (with one of the compatible fluids) between the administrations.

Do not use diluents containing calcium, such as Ringer's solution or Hartmann's solution, to reconstitute SUPRAVA vials or to further dilute a reconstituted vial for IV administration. Particulate formation can result.

NOTE: Parenteral drug products should be inspected visually for particulate matter before administration.

## STORAGE AND HANDLING INSTRUCTIONS

Store in a cool, dry place. Protect from light. Keep out of reach of children. Discard if reconstituted solution contains visible particulate matter. DISCARD UNUSED PORTION.

## How supplied

Vial with diluent in a carton

For further details, please contact:  
Medical Advisor  
**Biocon Limited**  
20th KM, Hosur Road, Electronics City,  
Bangalore - 560 100. India

Manufactured by:  
**Zeiss Pharmaceuticals Pvt. Ltd.**  
Plot No.72, EPIP, Phase-1, Jharmajri,  
Baddi, Dist. Solan, HP - 173205

Marketed by:  
**Biocon Limited**  
20th KM, Hosur Road, Electronics City,  
Bangalore - 560 100. India  
TM - Trade Mark of Biocon Limited

"Mfd. under the technical guidance of Biocon Limited"

To report adverse events and/or product complaints visit our website [www.biocon.com](http://www.biocon.com) or call toll free No: **1800 102 9465** or e mail us at [drugsafety@biocon.com](mailto:drugsafety@biocon.com)